Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,

Obesity is typically assessed by measuring someone's body mass index, but now researchers are calling for a more nuanced approach that could help with treatment

A global group of experts has suggested a new approach to diagnosing and treating obesity that does not rely solely on the much-contested body mass index (BMI).

Body Mass Index, or BMI, has long been criticized as an unreliable method for measuring obesity — and now a group of experts is sharing new recommendations for how to use it.

By coincidence (they started before GLP -1 drugs were approved for slimming), a group of 56 doctors have just answered that question. This group, called the Lancet Commission, and organised by the journal of that name, have developed a better way of diagnosing obesity—one that distinguishes when it has become pathological.

An international commission made the case for focusing on body fat quantity and the illnesses people experience.

Our reframing acknowledges the nuanced reality of obesity and allows for personalized care,” said Dr. Francesco Rubino of King’s College London.

Obesity, long determined by the flawed metric of BMI, should be diagnosed based on other measurements, experts argue.

Former Trump administration health official Joe Grogan applauds Biden proposal that Medicare and Medicaid cover GLP-1 weight-loss drugs — but says subjecting Wegovy to price controls is a bad move.

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy.Here's

People who enjoy a burger with fries on a night out aren’t to blame, and Americans should have every right to eat out at a restaurant without being unknowingly poisoned by heav